Navigation Links
Clay Aiken's Bubel/Aiken Foundation Raises Over $500,000 to Benefit Children With Disabilities at Gala Honoring the 2008 'Champions Of Change'
Date:11/24/2008

es through its more than 6,800 CVS/pharmacy and Longs Drugs stores; its Caremark Pharmacy Services division (pharmacy benefit management, mail order and specialty pharmacy); its retail-based health clinic subsidiary, MinuteClinic; and its online pharmacy, CVS.com. General information about CVS Caremark is available through the Investor Relations section of the Company's Web site, at http://cvscaremark.com/investors, as well as through the Newsroom section of the Company's Web site, at http://cvscaremark.com/newsroom.


'/>"/>
SOURCE The Bubel/Aiken Foundation
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine news :

1. National Patient Safety Foundation Partners with Vocera Communications
2. R. P. Simmons Family Foundation Pledges $2 Million for New Childrens Hospital of Pittsburgh of UPMC Campus
3. Patient Advocate Foundation Launches Program to Help Uninsured Virginians with Chronic, Debilitating and Life-Threatening Illness Access Quality Healthcare
4. AIDS Healthcare Foundation Applauds City Commissioners Support of Diversity, Urges Call for Mayors Resignation
5. National Osteoporosis Foundation Teams Up With Ladies Home Journal Magazine to Launch a 10-city Mall Walk Tour
6. Judge Rules That Florida Disease Management Program Serving 8,000 HIV/AIDS Patients Should Be Re-bid, Says AIDS Healthcare Foundation
7. The Tug McGraw Foundation Announces 2007 Fundraising Gala
8. The Arthur M. Blank Family Foundation Pushes for Pre-K Expansion in Georgia
9. Cipla, Tell the Truth; AIDS Healthcare Foundation Launches New Ad Campaign
10. Survey From The Partnership and MetLife Foundation Reveals Important Role Todays Grandparents Play in Teens Lives
11. Exceptional Childrens Foundation Merger with Kayne Eras Center Creates One of States Most Comprehensive Nonprofits Serving the Disabled
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:GSK Study Showed Targeted Therapy Combination Achieved 14 Month Overall Survival in Patients with Advanced Breast Cancer 2GSK Study Showed Targeted Therapy Combination Achieved 14 Month Overall Survival in Patients with Advanced Breast Cancer 3GSK Study Showed Targeted Therapy Combination Achieved 14 Month Overall Survival in Patients with Advanced Breast Cancer 4GSK Study Showed Targeted Therapy Combination Achieved 14 Month Overall Survival in Patients with Advanced Breast Cancer 5GSK Study Showed Targeted Therapy Combination Achieved 14 Month Overall Survival in Patients with Advanced Breast Cancer 6Pro-Dex, Inc. Announces Results of Annual Shareholder Meeting, an Update Regarding Major Customer's Product Development Plans, and Receipt of $1.5 Million and $3.0 Million Purchase Orders 2Pro-Dex, Inc. Announces Results of Annual Shareholder Meeting, an Update Regarding Major Customer's Product Development Plans, and Receipt of $1.5 Million and $3.0 Million Purchase Orders 3Pro-Dex, Inc. Announces Results of Annual Shareholder Meeting, an Update Regarding Major Customer's Product Development Plans, and Receipt of $1.5 Million and $3.0 Million Purchase Orders 4New Executive Leadership and CEO Announced for BiPar Sciences 2Study on keeping nuclear bombs from US ports shows misplaced fear over cargo scanning cost 12946 1Study on keeping nuclear bombs from US ports shows misplaced fear over cargo scanning cost 12946 2Study on keeping nuclear bombs from US ports shows misplaced fear over cargo scanning cost 12946 3Study on keeping nuclear bombs from US ports shows misplaced fear over cargo scanning cost 12946 4Research shows that invisible hand guides evolution of cooperative turn taking 9182 1Research shows that invisible hand guides evolution of cooperative turn taking 9182 2Rigel to Host Conference Call to Discuss Results of Its Phase 2b TASKi2 Clinical Trial of R788 in Rheumatoid Arthritis 4702 1Rigel to Host Conference Call to Discuss Results of Its Phase 2b TASKi2 Clinical Trial of R788 in Rheumatoid Arthritis 4702 2